Clinical Trials

Phase 1 Active not recruiting

Glioblastoma

NCT02287428 2026-04-17

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

56 enrolled

Glioblastoma

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

36 enrolled

Phase 2 Active not recruiting

Astrocytoma, Glioblastoma, Gliosarcoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

52 enrolled 19 charts

Glioblastoma, Gliosarcoma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

78 enrolled

Glioblastoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03405792 2026-02-06

2-THE-TOP

Phase 2 Active not recruiting

40 enrolled 11 charts

Phase 1 Not yet recruiting

Glioblastoma

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

8 enrolled

Turcot syndrome, Glioblastoma

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

28 enrolled

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

54 enrolled

Glioblastoma, Gliosarcoma

NCT06558214 2026-01-07

OPTIMUS PRIME

20 enrolled

Glioblastoma

NCT03426891 2025-10-06

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1 Completed

21 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT03347617 2025-09-09

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2 Terminated

52 enrolled 15 charts

Glioblastoma

NCT04977375 2025-09-03

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

10 enrolled

Phase 1 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT04201873 2025-08-22

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

40 enrolled

Phase 2 Active not recruiting

Glioblastoma

NCT02337686 2025-08-15

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

18 enrolled 12 charts

Glioblastoma, Gliosarcoma

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Phase 2 Withdrawn

Glioblastoma

NCT03018288 2025-08-08

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Phase 2 Terminated

90 enrolled 24 charts

Phase 1/2 Active not recruiting

Glioblastoma, Glioma

NCT04121455 2025-06-25

GLORIA

117 enrolled

Brain Neoplasms, Glioblastoma

NCT04479241 2025-06-05

LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

25 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT03665545 2025-05-13

IMA950-106

Phase 1/2 Completed

18 enrolled

Phase 3 Not yet recruiting

Glioblastoma

NCT06749925 2025-04-01

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

186 enrolled

Glioblastoma

NCT05879120 2024-11-20

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Phase 2 Withdrawn

Glioblastoma

NCT06640582 2024-11-05

BAH2472

85 enrolled

Phase 1/2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

179 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03661723 2024-09-19

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

60 enrolled 23 charts

Glioblastoma

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

41 enrolled 15 charts

Glioblastoma

NCT06157541 2024-05-31

TCaP

58 enrolled

Glioblastoma

NCT02530502 2023-11-18

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1 Terminated

4 enrolled

Glioblastoma

NCT05235737 2023-08-31

PIRG

Phase 4 Unknown

36 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma

NCT03726515 2023-06-22

CART-EGFRvIII + Pembrolizumab in GBM

Phase 1 Completed

7 enrolled

Glioblastoma

NCT05700955 2023-01-26

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

Phase 1 Unknown

30 enrolled

Glioblastoma

NCT05053880 2021-11-19

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Phase 1/2 Unknown

48 enrolled

Glioblastoma, Neoplasms

NCT02798406 2021-07-15

CAPTIVE

49 enrolled

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

NCT02337491 2020-12-22

Pembrolizumab +/- Bevacizumab for Recurrent GBM

80 enrolled 13 charts

Glioblastoma, Recurrence

NCT02430363 2016-02-24

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Phase 1/2 Unknown

58 enrolled